Format

Send to:

Choose Destination
See comment in PubMed Commons below
Am J Manag Care. 2007 Dec;13 Suppl 12:S319-26.

Into the light: strategies for battling hepatitis C.

Author information

  • 1Division of Gastroenterology and Hepatology, Saint Louis University, 3635 Vista Ave, FDT 9th Fl S, St. Louis, MO 63110, USA. baconbr@slu.edu

Abstract

The primary measurable goal of hepatitis C virus (HCV) therapy is permanent eradication of the virus (ie, a sustained virologic response [SVR]). Treatment decisions depend on the severity and treat ability of the infection, contraindications to treatment, and patient preferences. The current standard of treatment is combination therapy with pegylated interferon (peginterferon) and ribavirin. Dosages and treatment duration vary according to viral genotype. About 70% to 80% of patients with genotype 2 or 3 will achieve SVR compared with only 40% to 50% of patients with genotype 1. Generally, those who previously failed HCV treatment with monotherapy or standard interferon plus ribavirin should be considered for re-treatment with a trial of peginterferon and ribavirin. Side effects associated with treatment include influenzalike symptoms, insomnia, neutropenia, and hemolytic anemia and should be managed aggressively to promote patient adherence to therapy. Future pharmacologic agents are currently in development for patients failing treatment or those who have relapsed.

PMID:
18095780
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Managed Care & Healthcare Communications, LLC
    Loading ...
    Write to the Help Desk